N. А. Shamalov

Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial

Scott E. Kasner, Balakumar Swaminathan, Pablo M. Lavados et al. · The Lancet Neurology · 2018 · 178 citations · Full text

Medicine, Neurology, Pharmacotherapy +17

Embolic strokes of undetermined source: Prevalence and patient features in the ESUS Global Registry

Kanjana Perera, Thomas Vanassche, Jackie Bosch et al. · International Journal of Stroke · 2016 · 142 citations · Full text

Medicine, Clinical Sciences, Neurology +8

Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial

Robert G. Hart, Mukul Sharma, Hardi Mundl et al. · European Stroke Journal · 2016 · 98 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4·5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial

Eugene Gusev, M. Yu. Martynov, Alexey A Nikonov et al. · The Lancet Neurology · 2021 · 92 citations

Medicine, Neurology, Stroke Rehabilitation +10

Global Survey of the Frequency of Atrial Fibrillation–Associated Stroke

Kanjana Perera, Thomas Vanassche, Jackie Bosch et al. · Stroke · 2016 · 69 citations · Full text

Medicine, Cardiology, Clinical Cardiology +13